Superchain Procedures in Clinical Trials. George Kordzakhia FDA, CDER, Office of Biostatistics Alex Dmitrienko Quintiles Innovation
|
|
- Kelly Nicholson
- 5 years ago
- Views:
Transcription
1 August 01, 2012
2 Disclaimer: This presentation reflects the views of the author and should not be construed to represent the views or policies of the U.S. Food and Drug Administration
3 Introduction We describe a new class of multiple testing procedures for addressing multiplicity problems arising in clinical trials with multiple objectives grouped into families. The families may correspond to equally important sets of objectives, e.g., co-primary endpoints, or ordered sets of objectives, e.g., primary and secondary endpoints. The procedures, termed superchain procedures, serve as an extension of several classes of other multiple testing procedures, including chain procedures and parallel gatekeeping procedures.
4 Example 1: Two-family problem Clinical trial where experimental treatment is evaluated versus placebo at two dose levels (Dose 1, Dose 2) with respect to two endpoints (Endpoint 1, Endpoint 2). Four null hypotheses grouped into 2 families. Family Hypotheses Endpoint Comparison F 1 H 1 Endpoint 1 Dose 1 vs Placebo F 1 H 2 Endpoint 1 Dose 2 vs Placebo F 2 H 3 Endpoint 2 Dose 1 vs Placebo F 2 H 4 Endpoint 2 Dose 2 vs Placebo If two families may be treated as co-primary families, they can be tested simultaneously rather than sequentially.
5 procedure for two families Hypothesis testing problem with n null hypotheses grouped into 2 families: F 1 and F 2. The non-negative weights w 1 and w 2 with w 1 + w 2 =1 are assigned to F 1 and F 2 to quantify relative importance of the two families. At each step of the procedure, families F i, i =1, 2are tested simultaneously by component procedures P i at the α i level (to be specified). Component procedures P i, i =1,...,2, are derived using the closure principle and control the local FWER within F i.
6 procedure for two families At Step 1, families F i are tested at respective significance levels α i = w i α. Whenever one or more null hypotheses are rejected in a family, a certain fraction of FWER is released and can be transferred to other family. The transition parameters g ij 0 specify how the error rate is distributed. w 1 F 1 g 12 g 21 w 2 F 2
7 procedure for two families Truncated component procedures Assume that P i are truncated Hochberg (Holm or Hommel) procedures with truncation parameters 0 γ i 1. Truncated procedure is defined by computing a convex combination of the critical values of the original procedure with the critical values of the Bonferroni procedure based on the truncation parameter. Power of truncated procedures P i increases monotonically with the increase of γ i. Denote by γ i,0 the initial values of the truncation parameters for P i
8 procedure for two families Monotonicity (power pumping) Each null hypothesis that is rejected in F j, j i pumps the significance level for testing F i. The component procedures used in family F i, i =1, 2at each step of the algorithm, depend on the set of rejected null hypotheses in the other family denoted by R j, j i: P 1 P 1 [R 2 ], P 2 P 2 [R 1 ]. The truncation parameters γ i of P i grow monotonically as more null hypotheses are rejected in F j, j i. Thus, more powerfull tests are applied to all families at subsequent steps and the sets of testable hypotheses shrink from one step to the next.
9 Example 1 (continued) Clinical trial with four null hypotheses H 1, H 2, H 3, H 4 grouped into two families. Components are Hochberg based truncated Hochberg procedures Let 0 <γ i,0 < 1 denote the initial values of the truncation parameters for P i s Family Hypotheses Component Initial γ i F 1 H 1 H 2 Hochberg(γ 1 ) γ 1,0 =1/2 F 2 H 3 H 4 Hochberg(γ 2 ) γ 2,0 =1/2
10 Example 1 Consider case of equally weighted endpoints (Endpoints 1 and 2 are equally important): w 1 =1/2, w 2 =1/2. The families are logically related through the following graph with the transition weights g 12 and g 21 equal to F F 2
11 Example 1 Decision rules for truncated Hochberg Let ordered p-values in F 1 be p (1) < p (2). Hochberg (γ 1 ) rejects intersection hypothesis H 1 H 2 locally if p (1) < (γ 1 /2+(1 γ 1 )/2)α 1 = α 1 /2 or p (2) < (γ 1 +(1 γ 1 )/2)α 1 =(1+γ 1 )α 1 /2. Thus, within family F 1, both null hypotheses are rejected if p (2) (1 + γ 1 )α/2; only H (1) is rejected if p (1) α/2 andp (2) > (1 + γ 1 )α/2.
12 Example 1 Suppose the raw p-values for the null hypotheses are given by Hypotheses H 1 H 2 H 3 H 4 p-values The global FWER to be controlled at a one-sided α =0.025
13 Example 1 Step 1. Test F 1 by Hochberg(1/2) at level α 1 = α/2 = Since p 1 α 1 /2, and p 2 > (1 + γ 1,0 )α 1 /2=3α 1 /4, only H 1 is rejected, and, thus, R 1 = {H 1 }. Test F 2 by Hochberg(1/2) at level α 2 = α/2 = Since p 3 α 2 /2, and p 4 > (1 + γ 2,0 )α 2 /2=3α 2 /4, only H 3 is rejected. Thus, R 2 = {H 2 }.
14 Example 1 Updating significance levels, and truncation parameters ( α 1 = κ 1 α = w 1 + (1 γ ) 2,0) R 2 w 2 α = 5α n 2 8 Similarly, γ 1 = w 1 κ 1 γ 1,0 + κ 1 w 1 κ 1 1= 3 5. α 2 = 5α 8, γ 2 = 3 5.
15 Example 1 Step 2. Retest F 1 by Hochberg(3/5) at significance level α 1 =5α/8 = Since p 2 < (1 + γ 1 )α 1 /2=0.0125, both, H 1 and H 2 are rejected. Thus, R 1 = {H 1, H 2 }. Retest F 2 by Hochberg(3/5) at level α 2 =5α/8 = Since p 4 > (1 + γ 2 )α 2 /2=0.0125, no new rejections in F 2,andR 2 = {H 3 }.
16 Example 1 Step 3. Since all hypotheses in F 1 are rejected, retest F 2 by Hochberg(1) at full significance level α = p 4 < 0.025, and, thus, both hypotheses are rejected in F 2 The final set of null hypotheses rejected by the superchain procedure includes H 1, H 2, H 3, H 4.
17 procedure for multi-family problem Hypothesis testing problem with n null hypotheses grouped into m families: F 1,...,F m. Logical restrictions or connections among families F i are defined by a directed graph G where each node corresponds to exactly one family, and each directed edge represents a connection. The families F i are connected with each other to account for clinically relevant relationship among the families.
18 Graph G m nodes (one node for each family) w i 0 - family/node weights with w i 1, i g ij 0 - connection/edge weights with g ij 1. j
19 Example of a three-family graph w 1 F 1 g 21 g 13 g 12 g 31 w 2 g w 3 23 F 2 F 3 g 32
20 Overview At each step of the procedure, families are tested by component procedures. As long as the number of rejected hypotheses increases, the method allows to iterate retesting of the families with increasingly more powerful component procedures. If no additional null hypotheses are rejected at a step, the algorithm stops
21 Strong control of type I error rate Proposition The superchain procedure controls overall type I error rate at level α. Shown by constructing dominating closed testing procedure (mixture procedure) where each intersection is tested at an error rate at most α. Every null hypothesis that is rejected by the superchain procedure is also rejected by the corresponding mixture procedure.
22 Bretz, F., Maurer, W., Brannath, W., Posch, M. (2009). A graphical approach to sequentially rejective multiple test procedure. Statistics in Medicine. 28, , A., Tamhane, A.C., Wiens, B. (2008). General multistage gatekeeping procedures. Biometrical Journal. 50, , A.,, G., Tamhane, A.C. (2011). Multistage and mixture parallel gatekeeping procedures in clinical trials. Journal of Biopharmaceutical Statistics. Volume 21, Issie 4,
MULTISTAGE AND MIXTURE PARALLEL GATEKEEPING PROCEDURES IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 21: 726 747, 2011 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543406.2011.551333 MULTISTAGE AND MIXTURE PARALLEL
More informationBonferroni - based gatekeeping procedure with retesting option
Bonferroni - based gatekeeping procedure with retesting option Zhiying Qiu Biostatistics and Programming, Sanofi Bridgewater, NJ 08807, U.S.A. Wenge Guo Department of Mathematical Sciences New Jersey Institute
More informationAdaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests.
1/35 Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests. Martin Posch Center for Medical Statistics, Informatics and Intelligent Systems Medical University
More informationA Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications
A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications Thomas Brechenmacher (Dainippon Sumitomo Pharma Co., Ltd.) Jane Xu (Sunovion Pharmaceuticals Inc.) Alex Dmitrienko
More informationTesting a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials
Testing a secondary endpoint after a group sequential test Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 9th Annual Adaptive Designs in
More informationMixtures of multiple testing procedures for gatekeeping applications in clinical trials
Research Article Received 29 January 2010, Accepted 26 May 2010 Published online 18 April 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.4008 Mixtures of multiple testing procedures
More informationA note on tree gatekeeping procedures in clinical trials
STATISTICS IN MEDICINE Statist. Med. 2008; 06:1 6 [Version: 2002/09/18 v1.11] A note on tree gatekeeping procedures in clinical trials Alex Dmitrienko 1, Ajit C. Tamhane 2, Lingyun Liu 2, Brian L. Wiens
More informationOn Generalized Fixed Sequence Procedures for Controlling the FWER
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 On Generalized Fixed Sequence Procedures for Controlling the FWER Zhiying Qiu, a Wenge Guo b and Gavin Lynch c Testing
More informationAdaptive Dunnett Tests for Treatment Selection
s for Treatment Selection Franz König 1 Werner Brannath 1 Frank Bretz 2 Martin Posch 1 1 Section of Medical Statistics Medical University of Vienna 2 Novartis Pharma AG Basel Workshop Adaptive Designs
More informationType I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Frank Bretz Statistical Methodology, Novartis Joint work with Martin Posch (Medical University
More informationGroup sequential designs for Clinical Trials with multiple treatment arms
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework
More informationControl of Directional Errors in Fixed Sequence Multiple Testing
Control of Directional Errors in Fixed Sequence Multiple Testing Anjana Grandhi Department of Mathematical Sciences New Jersey Institute of Technology Newark, NJ 07102-1982 Wenge Guo Department of Mathematical
More informationThe Design of Group Sequential Clinical Trials that Test Multiple Endpoints
The Design of Group Sequential Clinical Trials that Test Multiple Endpoints Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Bruce Turnbull
More informationEstimation in Flexible Adaptive Designs
Estimation in Flexible Adaptive Designs Werner Brannath Section of Medical Statistics Core Unit for Medical Statistics and Informatics Medical University of Vienna BBS and EFSPI Scientific Seminar on Adaptive
More informationCompatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests
Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests K. Strassburger 1, F. Bretz 2 1 Institute of Biometrics & Epidemiology German Diabetes Center,
More informationA Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks
A Gatekeeping Test in a Group Sequential Design 1 A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks Ajit C. Tamhane Department of Industrial
More informationFamily-wise Error Rate Control in QTL Mapping and Gene Ontology Graphs
Family-wise Error Rate Control in QTL Mapping and Gene Ontology Graphs with Remarks on Family Selection Dissertation Defense April 5, 204 Contents Dissertation Defense Introduction 2 FWER Control within
More informationAlpha-recycling for the analyses of primary and secondary endpoints of. clinical trials
Alpharecycling for the analyses of primary and secondary endpoints of Presenters: clinical trials Mohammad Huque, Ph.D. FDA/CDER/OTS/ Office of Biostatistics Sirisha Mushti, Ph.D. Division of Biometrics
More informationStatistica Sinica Preprint No: SS R1
Statistica Sinica Preprint No: SS-2017-0072.R1 Title Control of Directional Errors in Fixed Sequence Multiple Testing Manuscript ID SS-2017-0072.R1 URL http://www.stat.sinica.edu.tw/statistica/ DOI 10.5705/ss.202017.0072
More informationAn Alpha-Exhaustive Multiple Testing Procedure
Current Research in Biostatistics Original Research Paper An Alpha-Exhaustive Multiple Testing Procedure, Mar Chang, Xuan Deng and John Balser Boston University, Boston MA, USA Veristat, Southborough MA,
More informationStepwise Gatekeeping Procedures in Clinical Trial Applications
984 Biometrical Journal 48 (2006) 6, 984 991 DOI: 10.1002/bimj.200610274 Stepwise Gatekeeping Procedures in Clinical Trial Applications Alex Dmitrienko *,1, Ajit C. Tamhane 2, Xin Wang 2, and Xun Chen
More informationMultiple Testing in Group Sequential Clinical Trials
Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas txz122@utdallas.edu 7/2/213 1 Sequential statistics
More informationOn weighted Hochberg procedures
Biometrika (2008), 95, 2,pp. 279 294 C 2008 Biometrika Trust Printed in Great Britain doi: 10.1093/biomet/asn018 On weighted Hochberg procedures BY AJIT C. TAMHANE Department of Industrial Engineering
More informationMultiple Testing. Anjana Grandhi. BARDS, Merck Research Laboratories. Rahway, NJ Wenge Guo. Department of Mathematical Sciences
Control of Directional Errors in Fixed Sequence arxiv:1602.02345v2 [math.st] 18 Mar 2017 Multiple Testing Anjana Grandhi BARDS, Merck Research Laboratories Rahway, NJ 07065 Wenge Guo Department of Mathematical
More informationFinding Critical Values with Prefixed Early. Stopping Boundaries and Controlled Type I. Error for A Two-Stage Adaptive Design
Finding Critical Values with Prefixed Early Stopping Boundaries and Controlled Type I Error for A Two-Stage Adaptive Design Jingjing Chen 1, Sanat K. Sarkar 2, and Frank Bretz 3 September 27, 2009 1 ClinForce-GSK
More informationAdaptive Treatment Selection with Survival Endpoints
Adaptive Treatment Selection with Survival Endpoints Gernot Wassmer Institut für Medizinische Statisti, Informati und Epidemiologie Universität zu Köln Joint wor with Marus Roters, Omnicare Clinical Research,
More informationHochberg Multiple Test Procedure Under Negative Dependence
Hochberg Multiple Test Procedure Under Negative Dependence Ajit C. Tamhane Northwestern University Joint work with Jiangtao Gou (Northwestern University) IMPACT Symposium, Cary (NC), November 20, 2014
More informationFamilywise Error Rate Controlling Procedures for Discrete Data
Familywise Error Rate Controlling Procedures for Discrete Data arxiv:1711.08147v1 [stat.me] 22 Nov 2017 Yalin Zhu Center for Mathematical Sciences, Merck & Co., Inc., West Point, PA, U.S.A. Wenge Guo Department
More informationAlpha-Investing. Sequential Control of Expected False Discoveries
Alpha-Investing Sequential Control of Expected False Discoveries Dean Foster Bob Stine Department of Statistics Wharton School of the University of Pennsylvania www-stat.wharton.upenn.edu/ stine Joint
More informationMultiple Testing of General Contrasts: Truncated Closure and the Extended Shaffer-Royen Method
Multiple Testing of General Contrasts: Truncated Closure and the Extended Shaffer-Royen Method Peter H. Westfall, Texas Tech University Randall D. Tobias, SAS Institute Pairwise Comparisons ANOVA, g =10groups,
More informationAdaptive clinical trials with subgroup selection
Adaptive clinical trials with subgroup selection Nigel Stallard 1, Tim Friede 2, Nick Parsons 1 1 Warwick Medical School, University of Warwick, Coventry, UK 2 University Medical Center Göttingen, Göttingen,
More informationAdaptive Designs: Why, How and When?
Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:
More informationA class of improved hybrid Hochberg Hommel type step-up multiple test procedures
Biometrika (2014), 101,4,pp. 899 911 doi: 10.1093/biomet/asu032 Printed in Great Britain Advance Access publication 24 October 2014 A class of improved hybrid Hochberg Hommel type step-up multiple test
More informationTesting a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial
Testing a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial ExL Pharma Workshop 2010 Rockville, MD Cyrus R. Mehta President, Cytel Corporation January 26, 2010 email: mehta@cytel.com
More informationAdaptive designs beyond p-value combination methods. Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013
Adaptive designs beyond p-value combination methods Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013 Outline Introduction Combination-p-value method and conditional error function
More informationMultistage Tests of Multiple Hypotheses
Communications in Statistics Theory and Methods, 39: 1597 167, 21 Copyright Taylor & Francis Group, LLC ISSN: 361-926 print/1532-415x online DOI: 1.18/3619282592852 Multistage Tests of Multiple Hypotheses
More informationLecture 6 April
Stats 300C: Theory of Statistics Spring 2017 Lecture 6 April 14 2017 Prof. Emmanuel Candes Scribe: S. Wager, E. Candes 1 Outline Agenda: From global testing to multiple testing 1. Testing the global null
More informationAdaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample Size Re-estimation
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.100/sim.0000 Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample
More informationGroup Sequential Trial with a Biomarker Subpopulation
Group Sequential Trial with a Biomarker Subpopulation Ting-Yu (Jeff) Chen, Jing Zhao, Linda Sun and Keaven Anderson ASA Biopharm Workshop, Sep 13th. 2018 1 Outline Motivation: Phase III PD-L1/PD-1 Monotherapy
More informationThe International Journal of Biostatistics
The International Journal of Biostatistics Volume 7, Issue 1 2011 Article 12 Consonance and the Closure Method in Multiple Testing Joseph P. Romano, Stanford University Azeem Shaikh, University of Chicago
More informationConfidence intervals and point estimates for adaptive group sequential trials
Confidence intervals and point estimates for adaptive group sequential trials Lingyun Liu, Ph.D. Cytel Inc. August 02, 2011 Miami, FL Lingyun Liu (Cytel Inc.) JSM August 02, 2011 Miami, FL 1 / 19 Acknowledgement
More informationComparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design
Comparing Adaptive Designs and the Classical Group Sequential Approach to Clinical Trial Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationSample Size and Power I: Binary Outcomes. James Ware, PhD Harvard School of Public Health Boston, MA
Sample Size and Power I: Binary Outcomes James Ware, PhD Harvard School of Public Health Boston, MA Sample Size and Power Principles: Sample size calculations are an essential part of study design Consider
More informationarxiv: v1 [math.st] 14 Nov 2012
The Annals of Statistics 2010, Vol. 38, No. 6, 3782 3810 DOI: 10.1214/10-AOS829 c Institute of Mathematical Statistics, 2010 arxiv:1211.3313v1 [math.st] 14 Nov 2012 THE SEQUENTIAL REJECTION PRINCIPLE OF
More informationPower assessment in group sequential design with multiple biomarker subgroups for multiplicity problem
Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong
More informationSequential/Adaptive Benchmarking
Sequential/Adaptive Benchmarking Manuel J. A. Eugster Institut für Statistik Ludwig-Maximiliams-Universität München Validation in Statistics and Machine Learning, 2010 1 / 22 Benchmark experiments Data
More informationPhilippe Delorme a, Pierre Lafaye de Micheaux a,
Package SSDDA : Sample Size Determination and Data Analysis in the context of continuous co-primary endpoints in clinical trials. Philippe Delorme a, Pierre Lafaye de Micheaux a, Benoît Liquet c,d and
More informationSimultaneous identifications of the minimum effective dose in each of several groups
Journal of Statistical Computation and Simulation Vol. 77, No. 2, February 2007, 149 161 Simultaneous identifications of the minimum effective dose in each of several groups SHOW-LI JAN*, YUH-ING CHEN
More informationStructured testing of 2 2 factorial effects: an analytic plan requiring fewer observations
Structured testing of 2 2 factorial effects: an analytic plan requiring fewer observations Dylan S. Small, Kevin G. Volpp, Paul R. Rosenbaum Department of Statistics and Department of Medicine University
More informationCHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity
CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity Prof. Kevin E. Thorpe Dept. of Public Health Sciences University of Toronto Objectives 1. Be able to distinguish among the various
More informationAnalysis of Multiple Endpoints in Clinical Trials
Chapter 4 Analysis of Multiple Endpoints in Clinical Trials Ajit C. Tamhane Northwestern University Alex Dmitrienko Eli Lilly and Company 4.1 Introduction Most human diseases are characterized by multidimensional
More informationOptimal exact tests for multiple binary endpoints
Optimal exact tests for multiple binary endpoints Robin Ristl 1, Dong Xi, Ekkehard Glimm 3,4, Martin Posch 1 December 3, 16 arxiv:161.7561v1 [stat.me] Dec 16 Abstract In confirmatory clinical trials with
More informationA Brief Introduction to Intersection-Union Tests. Jimmy Akira Doi. North Carolina State University Department of Statistics
Introduction A Brief Introduction to Intersection-Union Tests Often, the quality of a product is determined by several parameters. The product is determined to be acceptable if each of the parameters meets
More informationBLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES
BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES IBRAHIM TURKOZ, PhD Janssen Research & Development LLC, NJ BASS XX Nov, 013 BASS XX 1 Outline Introduction
More informationHigh-Throughput Sequencing Course. Introduction. Introduction. Multiple Testing. Biostatistics and Bioinformatics. Summer 2018
High-Throughput Sequencing Course Multiple Testing Biostatistics and Bioinformatics Summer 2018 Introduction You have previously considered the significance of a single gene Introduction You have previously
More informationType-II Generalized Family-Wise Error Rate Formulas with Application to Sample Size Determination
Type-II Generalized Family-Wise Error Rate Formulas with Application to Sample Size Determination Benoit Liquet 1,2, Pierre Lafaye de Micheaux 3 and Jérémie Riou 4 1 University de Pau et Pays de l Adour,
More informationThis paper has been submitted for consideration for publication in Biometrics
BIOMETRICS, 1 10 Supplementary material for Control with Pseudo-Gatekeeping Based on a Possibly Data Driven er of the Hypotheses A. Farcomeni Department of Public Health and Infectious Diseases Sapienza
More informationMultiple Testing. Hoang Tran. Department of Statistics, Florida State University
Multiple Testing Hoang Tran Department of Statistics, Florida State University Large-Scale Testing Examples: Microarray data: testing differences in gene expression between two traits/conditions Microbiome
More informationStep-down FDR Procedures for Large Numbers of Hypotheses
Step-down FDR Procedures for Large Numbers of Hypotheses Paul N. Somerville University of Central Florida Abstract. Somerville (2004b) developed FDR step-down procedures which were particularly appropriate
More informationROI ANALYSIS OF PHARMAFMRI DATA:
ROI ANALYSIS OF PHARMAFMRI DATA: AN ADAPTIVE APPROACH FOR GLOBAL TESTING Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Department of Statistics and Warwick Centre of Analytical Sciences,
More informationClosure properties of classes of multiple testing procedures
AStA Adv Stat Anal (2018) 102:167 178 https://doi.org/10.1007/s10182-017-0297-0 ORIGINAL PAPER Closure properties of classes of multiple testing procedures Georg Hahn 1 Received: 28 June 2016 / Accepted:
More informationConsonance and the Closure Method in Multiple Testing. Institute for Empirical Research in Economics University of Zurich
Institute for Empirical Research in Economics University of Zurich Working Paper Series ISSN 1424-0459 Working Paper No. 446 Consonance and the Closure Method in Multiple Testing Joseph P. Romano, Azeem
More informationApplying the Benjamini Hochberg procedure to a set of generalized p-values
U.U.D.M. Report 20:22 Applying the Benjamini Hochberg procedure to a set of generalized p-values Fredrik Jonsson Department of Mathematics Uppsala University Applying the Benjamini Hochberg procedure
More information2015 Duke-Industry Statistics Symposium. Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data
2015 Duke-Industry Statistics Symposium Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data Victoria Chang Senior Statistician Biometrics and Data Management
More informationTesting hypotheses in order
Biometrika (2008), 95, 1,pp. 248 252 C 2008 Biometrika Trust Printed in Great Britain doi: 10.1093/biomet/asm085 Advance Access publication 24 January 2008 Testing hypotheses in order BY PAUL R. ROSENBAUM
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH The First Step: SAMPLE SIZE DETERMINATION THE ULTIMATE GOAL The most important, ultimate step of any of clinical research is to do draw inferences;
More informationDesigning multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection
Research Article Statistics Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection Thomas
More informationgmcp - an R package for a graphical approach to weighted multiple test procedures
gmcp - an R package for a graphical approach to weighted multiple test procedures Kornelius Rohmeyer August 8, 6 Contents Introduction. Installation............................................... Basic
More informationControlling the False Discovery Rate in Two-Stage. Combination Tests for Multiple Endpoints
Controlling the False Discovery Rate in Two-Stage Combination Tests for Multiple ndpoints Sanat K. Sarkar, Jingjing Chen and Wenge Guo May 29, 2011 Sanat K. Sarkar is Professor and Senior Research Fellow,
More informationUNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION
UNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION BY MICHAEL ROSENBLUM Department of Biostatistics, Johns Hopkins Bloomberg
More informationOptimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives
Optimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives Thomas Ondra Sebastian Jobjörnsson Section for Medical Statistics, Medical
More informationMultiple Endpoints: A Review and New. Developments. Ajit C. Tamhane. (Joint work with Brent R. Logan) Department of IE/MS and Statistics
1 Multiple Endpoints: A Review and New Developments Ajit C. Tamhane (Joint work with Brent R. Logan) Department of IE/MS and Statistics Northwestern University Evanston, IL 60208 ajit@iems.northwestern.edu
More informationUniversity of California, Berkeley
University of California, Berkeley U.C. Berkeley Division of Biostatistics Working Paper Series Year 2010 Paper 267 Optimizing Randomized Trial Designs to Distinguish which Subpopulations Benefit from
More informationA NEW APPROACH FOR LARGE SCALE MULTIPLE TESTING WITH APPLICATION TO FDR CONTROL FOR GRAPHICALLY STRUCTURED HYPOTHESES
A NEW APPROACH FOR LARGE SCALE MULTIPLE TESTING WITH APPLICATION TO FDR CONTROL FOR GRAPHICALLY STRUCTURED HYPOTHESES By Wenge Guo Gavin Lynch Joseph P. Romano Technical Report No. 2018-06 September 2018
More informationSleep data, two drugs Ch13.xls
Model Based Statistics in Biology. Part IV. The General Linear Mixed Model.. Chapter 13.3 Fixed*Random Effects (Paired t-test) ReCap. Part I (Chapters 1,2,3,4), Part II (Ch 5, 6, 7) ReCap Part III (Ch
More informationInterim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping
Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically,
More informationSequential tests controlling generalized familywise error rates
Sequential tests controlling generalized familywise error rates Shyamal K. De a, Michael Baron b,c, a School of Mathematical Sciences, National Institute of Science Education and Research, Bhubaneswar,
More informationTechnical Manual. 1 Introduction. 1.1 Version. 1.2 Developer
Technical Manual 1 Introduction 1 2 TraditionalSampleSize module: Analytical calculations in fixed-sample trials 3 3 TraditionalSimulations module: Simulation-based calculations in fixed-sample trials
More informationA superiority-equivalence approach to one-sided tests on multiple endpoints in clinical trials
Biometria (24), 91, 3, pp. 715 727 24 Biometria Trust Printed in Great Britain A superiority-equivalence approach to one-sided tests on multiple endpoints in clinical trials BY AJIT C. TAMHANE Department
More informationMULTIPLE TESTING TO ESTABLISH SUPERIORITY/EQUIVALENCE OF A NEW TREATMENT COMPARED WITH k STANDARD TREATMENTS
STATISTICS IN MEDICINE, VOL 16, 2489 2506 (1997) MULTIPLE TESTING TO ESTABLISH SUPERIORITY/EQUIVALENCE OF A NEW TREATMENT COMPARED WITH k STANDARD TREATMENTS CHARLES W DUNNETT* AND AJIT C TAMHANE Department
More informationTests about a population mean
October 2 nd, 2017 Overview Week 1 Week 2 Week 4 Week 7 Week 10 Week 12 Chapter 1: Descriptive statistics Chapter 6: Statistics and Sampling Distributions Chapter 7: Point Estimation Chapter 8: Confidence
More informationStatistical Applications in Genetics and Molecular Biology
Statistical Applications in Genetics and Molecular Biology Volume 5, Issue 1 2006 Article 28 A Two-Step Multiple Comparison Procedure for a Large Number of Tests and Multiple Treatments Hongmei Jiang Rebecca
More informationTwo-Phase, Three-Stage Adaptive Designs in Clinical Trials
Japanese Journal of Biometrics Vol. 35, No. 2, 69 93 (2014) Preliminary Report Two-Phase, Three-Stage Adaptive Designs in Clinical Trials Hiroyuki Uesaka 1, Toshihiko Morikawa 2 and Akiko Kada 3 1 The
More informationSummary and discussion of: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Summary and discussion of: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing Statistics Journal Club, 36-825 Beau Dabbs and Philipp Burckhardt 9-19-2014 1 Paper
More information6 Sample Size Calculations
6 Sample Size Calculations A major responsibility of a statistician: sample size calculation. Hypothesis Testing: compare treatment 1 (new treatment) to treatment 2 (standard treatment); Assume continuous
More informationADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES
ADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES Christopher Jennison Department of Mathematical Sciences, University of Bath, Bath BA2 7AY, U. K. email: cj@maths.bath.ac.uk and
More informationGroup Sequential Designs: Theory, Computation and Optimisation
Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference
More informationIEOR165 Discussion Week 12
IEOR165 Discussion Week 12 Sheng Liu University of California, Berkeley Apr 15, 2016 Outline 1 Type I errors & Type II errors 2 Multiple Testing 3 ANOVA IEOR165 Discussion Sheng Liu 2 Type I errors & Type
More informationTwo-stage k-sample designs for the ordered alternative problem
Two-stage k-sample designs for the ordered alternative problem Guogen Shan, Alan D. Hutson, and Gregory E. Wilding Department of Biostatistics,University at Buffalo, Buffalo, NY 14214, USA July 18, 2011
More informationLooking at the Other Side of Bonferroni
Department of Biostatistics University of Washington 24 May 2012 Multiple Testing: Control the Type I Error Rate When analyzing genetic data, one will commonly perform over 1 million (and growing) hypothesis
More informationMathematical statistics
October 20 th, 2018 Lecture 17: Tests of Hypotheses Overview Week 1 Week 2 Week 4 Week 7 Week 10 Week 14 Probability reviews Chapter 6: Statistics and Sampling Distributions Chapter 7: Point Estimation
More informationdiscovery rate control
Optimal design for high-throughput screening via false discovery rate control arxiv:1707.03462v1 [stat.ap] 11 Jul 2017 Tao Feng 1, Pallavi Basu 2, Wenguang Sun 3, Hsun Teresa Ku 4, Wendy J. Mack 1 Abstract
More informationOn Procedures Controlling the FDR for Testing Hierarchically Ordered Hypotheses
On Procedures Controlling the FDR for Testing Hierarchically Ordered Hypotheses Gavin Lynch Catchpoint Systems, Inc., 228 Park Ave S 28080 New York, NY 10003, U.S.A. Wenge Guo Department of Mathematical
More informationMultiple testing: Intro & FWER 1
Multiple testing: Intro & FWER 1 Mark van de Wiel mark.vdwiel@vumc.nl Dep of Epidemiology & Biostatistics,VUmc, Amsterdam Dep of Mathematics, VU 1 Some slides courtesy of Jelle Goeman 1 Practical notes
More informationarxiv: v2 [stat.me] 6 Sep 2013
Sequential Tests of Multiple Hypotheses Controlling Type I and II Familywise Error Rates arxiv:1304.6309v2 [stat.me] 6 Sep 2013 Jay Bartroff and Jinlin Song Department of Mathematics, University of Southern
More informationGroup-Sequential Tests for One Proportion in a Fleming Design
Chapter 126 Group-Sequential Tests for One Proportion in a Fleming Design Introduction This procedure computes power and sample size for the single-arm group-sequential (multiple-stage) designs of Fleming
More informationControl of Generalized Error Rates in Multiple Testing
Institute for Empirical Research in Economics University of Zurich Working Paper Series ISSN 1424-0459 Working Paper No. 245 Control of Generalized Error Rates in Multiple Testing Joseph P. Romano and
More informationOptimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping
: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology
More informationCase Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial William R. Gillespie Pharsight Corporation Cary, North Carolina, USA PAGE 2003 Verona,
More information